Psychedelic API Market Size, Share, and Trends 2025 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology 

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Psychedelic API Market

5.1. COVID-19 Landscape: Psychedelic API Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Psychedelic API Market, By Molecule / Class

8.1. Psychedelic API Market Revenue and Volume, by Molecule / Class

8.1.1. Psilocybin / Psilocin

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. MDMA    

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Lysergide / LSD

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Tryptamines

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Iboga Alkaloids

8.1.5.1. Market Revenue and Volume Forecast

8.1.6. Next-gen 5-HT2A modulators / psychoplastogens

8.1.6.1. Market Revenue and Volume Forecast

8.1.7 Ketamine Class

8.1.7.1. Market Revenue and Volume Forecast

Chapter 9. Global Psychedelic API Market, By Source / Synthesis Route

9.1. Psychedelic API Market Revenue and Volume, by Source / Synthesis Route

9.1.1. Fully synthetic

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Biosynthetic / fermentation

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Semi-synthetic

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Botanical / fungal extraction

9.1.4.1. Market Revenue and Volume Forecast

Chapter 10. Global Psychedelic API Market, By Form / Solid-State & Grade

10.1. Psychedelic API Market Revenue and Volume, by Form / Solid-State & Grade

10.1.1. Salt forms

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Base forms

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Polymorph / crystal forms

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Micronized / particle-size controlled grades

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global Psychedelic API Market, By Contracting Model

11.1. Psychedelic API Market Revenue and Volume, by Contracting Model

11.1.1. CDMO outsourcing (development to scale)

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Captive / in-house API

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Dual-sourcing / tech transfer

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Pathway / IP licensing (biosynthesis)

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Psychedelic API Market, By End Use

12.1. Psychedelic API Market Revenue and Volume, by End Use

12.1.1. Branded Rx developers / sponsors   

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Clinic networks / licensed compounding

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. State-regulated service providers

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Academic / investigator-initiated programs

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. Global Psychedelic API Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Molecule / Class

13.1.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.1.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.1.4. Market Revenue and Volume Forecast, by Contracting Model

13.1.5. Market Revenue and Volume Forecast, by End Use

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Molecule / Class

13.1.6.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.1.6.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.1.6.4. Market Revenue and Volume Forecast, by Contracting Model

13.1.6.5. Market Revenue and Volume Forecast, by End Use 

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Molecule / Class

13.1.7.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.1.7.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.1.7.4. Market Revenue and Volume Forecast, by Contracting Model

13.1.7.5. Market Revenue and Volume Forecast, by End Use

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Molecule / Class

13.2.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.2.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.2.4. Market Revenue and Volume Forecast, by Contracting Model 

13.2.5. Market Revenue and Volume Forecast, by End Use 

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Molecule / Class

13.2.6.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.2.6.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.2.7. Market Revenue and Volume Forecast, by Contracting Model 

13.2.8. Market Revenue and Volume Forecast, by End Use 

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Molecule / Class

13.2.9.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.2.9.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.2.10. Market Revenue and Volume Forecast, by Contracting Model

13.2.11. Market Revenue and Volume Forecast, by End Use

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Molecule / Class

13.2.12.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.2.12.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.2.12.4. Market Revenue and Volume Forecast, by Contracting Model

13.2.13. Market Revenue and Volume Forecast, by End Use

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Molecule / Class

13.2.14.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.2.14.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.2.14.4. Market Revenue and Volume Forecast, by Contracting Model

13.2.15. Market Revenue and Volume Forecast, by End Use

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Molecule / Class

13.3.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.3.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.3.4. Market Revenue and Volume Forecast, by Contracting Model

13.3.5. Market Revenue and Volume Forecast, by End Use

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Molecule / Class

13.3.6.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.3.6.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.3.6.4. Market Revenue and Volume Forecast, by Contracting Model

13.3.7. Market Revenue and Volume Forecast, by End Use

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Molecule / Class

13.3.8.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.3.8.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.3.8.4. Market Revenue and Volume Forecast, by Contracting Model

13.3.9. Market Revenue and Volume Forecast, by End Use

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Molecule / Class

13.3.10.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.3.10.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.3.10.4. Market Revenue and Volume Forecast, by Contracting Model

13.3.10.5. Market Revenue and Volume Forecast, by End Use

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Molecule / Class

13.3.11.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.3.11.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.3.11.4. Market Revenue and Volume Forecast, by Contracting Model

13.3.11.5. Market Revenue and Volume Forecast, by End Use

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Molecule / Class

13.4.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.4.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.4.4. Market Revenue and Volume Forecast, by Contracting Model

13.4.5. Market Revenue and Volume Forecast, by End Use

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Molecule / Class

13.4.6.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.4.6.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.4.6.4. Market Revenue and Volume Forecast, by Contracting Model

13.4.7. Market Revenue and Volume Forecast, by End Use

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Molecule / Class

13.4.8.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.4.8.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.4.8.4. Market Revenue and Volume Forecast, by Contracting Model

13.4.9. Market Revenue and Volume Forecast, by End Use

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Molecule / Class

13.4.10.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.4.10.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.4.10.4. Market Revenue and Volume Forecast, by Contracting Model

13.4.10.5. Market Revenue and Volume Forecast, by End Use

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Molecule / Class

13.4.11.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.4.11.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.4.11.4. Market Revenue and Volume Forecast, by Contracting Model

13.4.11.5. Market Revenue and Volume Forecast, by End Use

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Molecule / Class

13.5.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.5.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.5.4. Market Revenue and Volume Forecast, by Contracting Model

13.5.5. Market Revenue and Volume Forecast, by End Use

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Molecule / Class

13.5.6.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.5.6.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.5.6.4. Market Revenue and Volume Forecast, by Contracting Model

13.5.7. Market Revenue and Volume Forecast, by End Use

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Molecule / Class

13.5.8.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

13.5.8.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

13.5.8.4. Market Revenue and Volume Forecast, by Contracting Model

13.5.8.5. Market Revenue and Volume Forecast, by End Use

Chapter 14. Company Profiles

14.1. Compass Pathways   

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. MindMed   

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Atai Life Sciences

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Cybin Inc

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Usona Institute

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Delic Holdings Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Havn Life Sciences

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Beckley Psytech

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Psilera Inc.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. NeonMind Biosciences

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Term